Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

被引：9

作者：

Karaca, Halit ^{[1
]}

Lale, Ayhan ^{[2
]}

Dikilitas, Mustafa ^{[1
]}

Ozkan, Metin ^{[1
]}

Er, Ozlem ^{[1
]}

机构：

[1] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey

[2] Erciyes Univ, Dept Internal Med, Fac Med, Kayseri, Turkey

来源：

MEDICAL ONCOLOGY | 2010年 / 27卷 / 03期

关键词：

Renal cell carcinoma; Paraneoplastic hypercalcemia; Sunitinib; TYROSINE KINASE INHIBITOR; GROWTH-FACTOR; SU11248; CANCER; INTERFERON; SURVIVAL;

D O I：

10.1007/s12032-009-9327-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor. It has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-a. We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.

引用

页码：1023 / 1026

页数：4

共 27 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[3] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[4] MANAGEMENT AND PROGNOSTIC-SIGNIFICANCE OF HYPERCALCEMIA IN RENAL-CELL CARCINOMA [J].

CHASAN, SA ;

POTHEL, LR ;

HUBEN, RP .

UROLOGY, 1989, 33 (03) :167-170

[5]

ENDO I, 2006, CLIN CALCIUM, V16, P373

[6] Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia [J].

Er, Ö ;

Coskun, HS ;

Altinbas, M ;

Akgün, H ;

Çetin, M ;

Eser, B ;

Ünal, A .

UROLOGIA INTERNATIONALIS, 2001, 67 (02) :175-177

[7] Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms [J].

Erber, R ;

Thurnher, A ;

Katsen, AD ;

Groth, G ;

Kerger, H ;

Hammes, HP ;

Menger, MD ;

Ullrich, A ;

Vajkoczy, P .

FASEB JOURNAL, 2003, 17 (15) :338-340

[8] Cytokines in metastatic renal cell carcinoma:: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment? [J].

Escudier, B ;

Chevreau, C ;

Lasset, C ;

Douillard, JY ;

Ravaud, A ;

Fabbro, M ;

Caty, A ;

Rossi, JF ;

Viens, P ;

Bergerat, JP ;

Savary, J ;

Négrier, S .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2039-2043

[9]

GANESH SP, 2002, REV UROL, V4, P163

[10]

KAELIN WG, 2005, BIOCHEM BIOPH RES CO, V23, P240

← 1 2 3 →